CBG Atlas

Safety & reporting
AtlasExplainersTRP channels and cannabinoids: TRPV1, TRPV2, and TRPM8
How we grade evidenceGlossaryCBG Monograph
Explainer

TRP channels and cannabinoids: TRPV1, TRPV2, and TRPM8

The burn of a chili pepper starts at a channel called TRPV1, which capsaicin, the "hot" compound in the pepper, pries open. The chill of mint starts at another, TRPM8, which answers to menthol and to cold. These TRP (transient receptor potential) channels are the body's molecular sensors: small gated pores in the surface of nerve and other cells that detect temperature and certain chemicals and turn them into nerve signals, with TRPV2, a related channel, responding to heat. Several cannabinoids act on them directly. In laboratory studies, CBG desensitises the TRPV1 and TRPV2 channels and antagonises, or blocks, TRPM8 (De Petrocellis 2011). That makes it a demonstrated interaction in a dish, not a demonstrated effect in people. Demonstrated · in vitro

The map

The TRP channels in one drawing.

A sensory nerve ending's membrane with four gated pores in it, what opens each, the signal it starts, and where CBG acts in the laboratory. Every node is repeated in words beneath the drawing.

Figure O · TRP channels and cannabinoids
Four gated pores in a sensory nerve ending: what opens each channel, the signal it starts, and where CBG acts on it in the laboratory
A sensory nerve ending's outer membrane in cross-section, with four TRP channels drawn as gated pores straddling it. Above the membrane sits the stimulus that opens each channel: painful heat and capsaicin, the chili compound, for TRPV1; cold and menthol for TRPM8; very high heat, in cell studies, for TRPV2, a relative of TRPV1; and wasabi and mustard oil for TRPA1, the irritant sensor. When a channel opens, ions flow through the pore into the nerve ending and a nerve signal begins. A lower band shows CBG's action in laboratory cell studies from De Petrocellis 2011: at TRPV1 and TRPV2 it activates the channel and then desensitises it, drawn as a first burst beside a quiet channel; at TRPM8 it blocks the channel, which is drawn shut behind a bar, with no burst first. TRPA1 is drawn lighter, in a dashed frame: the registry holds no graded CBG interaction there. Two notes close the figure: some researchers call the TRP channels the extended endocannabinoid system, and they sit apart from CB1 and CB2; and an interaction in a dish is not an effect in people, so nothing here is pain relief. All CBG findings are in vitro and graded Demonstrated, not human effects.A sensory nerve ending · four TRP channels, each a gated pore in its membraneWhere CBG acts · in cells in a dish, not in peopleoutside the nervepainful heat and capsaicinopen the channelcold and mentholopen the channelvery high heat, in cells,opens the channelwasabi and mustard oilopen the channelinside the nerve ending · the membrane is the double lineTRPV1the heat and capsaicin sensorTRPM8the cold and menthol sensorTRPV2a heat-responsive relative, in cellsTRPA1the irritant sensorions flow ina nerve signal beginsions flow ina nerve signal beginsions flow ina nerve signal beginsions flow ina nerve signal beginsCBG activates,then desensitisesfirst, a burstthen quietagonist–desensitiser, in vitroDe Petrocellis 2011CBG blocks TRPM8without switching it on firstless responsive, no burstantagonist, in vitroDe Petrocellis 2011CBG activates,then desensitisesfirst, a burstthen quietagonist–desensitiser, in vitroDe Petrocellis 2011CBG at TRPA1:no graded interactionin our registrySome researchers call the TRP channels the extended endocannabinoid system; they sit apart from CB1 and CB2.An interaction in a dish is not an effect in people; nothing here is pain relief.
The gated pore and the nerve signal
A TRP channel is an ion channel, a gated pore in the cell membrane: when a physical or chemical stimulus opens it, charged particles such as calcium and sodium ions flow into the cell and an electrical nerve signal begins. Many sit in sensory nerve endings. grade: Established
TRPV1
The heat and capsaicin sensor: painful heat opens it, and so does capsaicin, the chili compound. grade: Established CBG: activates, then desensitises (agonist–desensitiser), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
TRPM8
The cold and menthol sensor: cool temperatures open it, as does menthol, and it is the main route by which the body detects cooling. grade: Established CBG: blocks the channel (antagonist), without switching it on first, in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
TRPV2
A heat-responsive relative of TRPV1 in the vanilloid branch of the family; its identity and heat responsiveness are textbook, and its wider role, less fully mapped, carries no claim here. grade: Established CBG: activates, then desensitises (agonist–desensitiser), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
TRPA1
The irritant sensor, the channel that makes wasabi and mustard oil sting; drawn lighter because it is in the family and not in CBG's graded record. grade: Established CBG: no graded interaction in our registry (an absence in our record, not a finding against one).
Desensitisation
A desensitising compound first switches a channel on; with continued exposure the channel stops responding and goes quiet. The two small states in the CBG band draw that sequence: a first burst, then a quiet channel. Antagonism, CBG's action at TRPM8, is simpler: the compound makes the channel less responsive without switching it on first. grade: Established
The channels and their gating are textbook sensory physiology, drawn in ink and forest and graded Established on the explainer they sit in. CBG's interactions are drawn in oxblood: a bar where it blocks a channel, a chevron and a bar where it activates one and then desensitises it, each with the registry study behind it. They were measured in cells in a dish, which is what Demonstrated · in vitro means, and none of them is an effect in people. Where the registry holds no graded CBG interaction the node says so in a dashed frame. Source: De Petrocellis 2011. See the monograph's target map for the same record at researcher depth. The endocannabinoid system has a map of its own →

For anyone building a product on that finding, the question is how far the result travels. So far, about as far as the edge of the dish.

The grades, and the gap between them. What these channels are, and how CBG behaves toward them in the laboratory, can be stated with a grade. What that means for a person (pain, itch, temperature sensation, skin) is a claim that belongs to whoever makes it, limits attached, because no human study connects CBG's channel activity to any outcome. The ladder has six rungs: the six-rung evidence ladder. Not supported is reserved for a question that has been tested and has come back against the claim. An untested question, one with no primary study in our registry, gets No primary evidence / catalogue in progress instead, which marks a gap in coverage and sits off the ladder. None of it is medical, legal, or professional advice.

What TRP channels do

Start with the hardware. A TRP channel is an ion channel, a gated pore in the cell membrane: when a physical or chemical stimulus opens it, charged particles such as calcium and sodium ions flow into the cell and an electrical nerve signal begins. Many of these channels sit in sensory nerve endings, where they work as the body's thermometers and chemical detectors. The biology is well established, and the discovery of the temperature sensors earned the 2021 Nobel Prize in Physiology or Medicine. Established

  • TRPV1 responds to heat and capsaicin. Painful heat opens it, and so does capsaicin. Sensory biologists know few channels better. Established
  • TRPM8 responds to cold and menthol. Cool temperatures open it, as does menthol, and it is the main route by which the body detects cooling. Established
  • TRPV2 is a heat-responsive relative of TRPV1. Both belong to the vanilloid branch, though TRPV2's wider role is less fully mapped than those of TRPV1 and TRPM8. Established (identity and heat responsiveness); its broader roles are Emerging.

The family runs well past these three. TRPA1, for example, is the "irritant" sensor that makes wasabi and mustard oil sting, and different cannabinoids act on different members of the family. Established

How CBG acts on TRP channels

Now put CBG in the dish. In laboratory (in vitro) studies it acts on all three channels, in two quite different ways (De Petrocellis 2011), and we describe those interactions in words only, leaving out the exact binding and potency figures. Demonstrated · in vitro

What "desensitisation" means. The word suggests a dampener, and that is where it ends up, but it starts as the opposite. A desensitising compound first switches a channel on; with continued exposure the channel stops responding and goes quiet. Capsaicin (chili) creams work on the same principle, a first burst of activation followed by a silent sensor, so an agonist that desensitises can end up damping the very signal it set off. CBG treats TRPV1 and TRPV2 this way. Antagonism, its action at TRPM8, is simpler: the compound makes the channel less responsive without switching it on first. Established (these are standard pharmacology concepts)

The channels are only part of CBG's laboratory profile. In vitro it also acts as a CB₁ receptor competitive antagonist and acts on α₂-adrenoceptors and 5-HT₁ₐ serotonin receptors (Cascio 2010). Because those α₂-adrenoceptors help regulate blood pressure, anyone taking cardiovascular medication should speak with a clinician before using CBG products. Demonstrated · in vitro for the receptor activity; the blood-pressure point is a precaution rather than a measured clinical effect.

What the findings show, and where they stop

Which leaves the question a buyer actually cares about. What has been shown is narrow: CBG binds and modulates TRPV1, TRPV2 and TRPM8 in cells in a dish. Nobody has shown that it relieves pain, alters how a person senses heat or cold, calms itch, or treats any skin or sensory condition. The interaction itself is Demonstrated · in vitro. What it means for people sits between Emerging and Hypothesized at best, and for any specific condition it is not established.

  • Cells in a dish are not patients. Inside a living body, dose, absorption, distribution and thousands of competing signals all shape what a molecule does, so activity at a channel in isolated cells may fail to carry over. The lab result is a lead for research, short of a result. Established (as a principle of evidence)
  • The lead is still worth following. Pain, temperature sensation, itch and inflammation all involve TRP channels, which is why researchers study them, and CBG's in vitro activity there is a reasonable place to start. The channels' role is well established; a useful effect of CBG on them in people remains a hypothesis. Established (TRP biology) / Hypothesized (CBG benefit)
  • No human trial links the two. In our registry, CBG's entire human evidence base is a single small trial, and it asked a different question, about acute anxiety and stress, so the channel activity has not been tied to any outcome in a controlled human study. Elsewhere CBG has preclinical (animal) signals, including an anti-inflammatory effect in a mouse colitis model (Borrelli 2013), though that result says nothing about TRP channels in particular and is not established in humans. Emerging · preclinical
  • The bottom line. CBG–TRP interaction = Demonstrated · in vitro. Any consumer benefit drawn from it = not established (catalogue in progress). Copy that leaps from "acts on the heat receptor" to "relieves pain" skips every step in between.

Common questions

Do cannabinoids act on TRP channels?

Yes, several do in laboratory studies. CBG desensitises TRPV1 and TRPV2 and blocks TRPM8 (De Petrocellis 2011), while other cannabinoids work on other members of the family; CBN, for instance, acts on the irritant sensor TRPA1 in vitro. All of these interactions were seen in vitro, and none has been shown to produce an effect in people. Demonstrated · in vitro

Does CBG activate or block TRP channels?

Both, depending on the channel. CBG turns TRPV1 and TRPV2 on as an agonist and then desensitises them, so that with continued exposure they fall quiet; TRPM8 it blocks outright, acting as an antagonist. De Petrocellis 2011 reported all three effects in laboratory cell studies. Demonstrated · in vitro

What is "desensitisation," in plain terms?

Desensitisation happens when a sensor is switched on and then, under continued exposure, stops responding. Capsaicin creams rely on it: the first activation gives way to nerve endings that fall silent, which is how a compound that first activates a channel can end up reducing its signalling. Established

Does CBG's effect on TRPV1 mean it relieves pain?

That link is not established. TRPV1 is studied for its part in heat and pain sensing, and CBG acts on it in the laboratory, but the chain stops there: no controlled human study shows CBG relieving pain, and an in vitro interaction is not a treatment. Pain-relief claims made for CBG products are unproven. (Not medical advice.) No primary evidence

Should I use a CBG product for pain, itch, or skin because of its TRP activity?

The TRP activity offers no evidence-based reason to. It was seen only in the laboratory, any benefit to people remains undemonstrated, and no CBG dose has been established. Because CBG also acts on α₂-adrenoceptors that help regulate blood pressure (Cascio 2010), anyone on cardiovascular medication should consult a clinician first. (Not medical advice.) No primary evidence

Sources

  • De Petrocellis 2011 · PMID 21175579 · Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes, British Journal of Pharmacology. The main source: in cell studies, CBG activated then desensitised TRPV1 and TRPV2 and blocked TRPM8. Grade: Demonstrated · in vitro.
  • Cascio 2010 · PMID 20002104 · Evidence that the plant cannabinoid cannabigerol is a highly potent α₂-adrenoceptor agonist and moderately potent 5-HT₁ₐ receptor antagonist, British Journal of Pharmacology. The α₂ / blood-pressure caution rests on it. Grade: Demonstrated · in vitro.
  • Borrelli 2013 · PMID 23415610 · CBG reduced inflammation in mice with experimental colitis. Grade: Emerging · preclinical; not established in humans.
  • TRP channel biology, including TRPV1's response to heat and capsaicin and TRPM8's response to cold and menthol, is Established general physiology. Binding and potency figures are omitted, and so is dosing, since no CBG dose exists to report.
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
The six rungs, and the words each one permits
grade: Established
Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
grade: Demonstrated
Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
grade: Emerging
An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
grade: Low
Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
grade: Hypothesized
Proposed and plausible — but not yet shown. “proposed mechanism”
grade: Not supported
Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
Catalogue in progress
Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.

A grade rates the support for a claim across the literature, never a single study. How we grade evidence.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring